MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Country |
 USA |
IPO year |
1992 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
1.24 B |
Market Cap[1] |
$ 164 B |
EBITDA (LTM) |
$ 9.3 B |
P/E (LTM) |
21.48 |
P/S (LTM) |
5.6 |
EPS (LTM) |
6.09 |
Gilead Sciences is an American biopharmaceutical company that specializes in the development and production of innovative drugs for the treatment of various diseases.
The company was founded in 1987 and is currently one of the leaders in the field of biotechnology. It conducts research and development in areas such as infectious diseases, oncology, hepatitis, HIV infection, and other areas of medicine.
The company's most well-known and successful product is Sovaldi, which is the first drug to effectively treat chronic hepatitis C. The company also produces drugs for the treatment of blood cancer and HIV infection.
Gilead Sciences actively collaborates with scientific and medical institutions around the world and invests in the development of new methods for treating diseases. The company also provides training programs for medical professionals and patients.
Gilead Sciences continues to grow and expand its activities to help people around the world fight various diseases.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
BioNTech SE
BNTX
|
$ 97.54 | -5.71 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Burford Capital Limited
BUR
|
$ 5.2 | 5.69 % | $ 820 M | NYSE |  Britain |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
Cerus Corporation
CERS
|
$ 2.72 | 33.99 % | $ 518 M | Nasdaq Global Market | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 21.95 | -2.23 % | $ 3.64 B | Nasdaq Global Select Market,SPB | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market |  Israel |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | USA |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | USA |
 |
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Cardiff Oncology
CRDF
|
$ 1.71 | -1.16 % | $ 114 M | Nasdaq Capital Market | USA |
 |
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Editas Medicine
EDIT
|
$ 2.9 | -3.33 % | $ 257 M | Nasdaq Global Select Market,SPB | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | Nasdaq Capital Market | USA |
 |
Edesa Biotech
EDSA
|
$ 17.59 | -3.75 % | $ 56.2 M | Nasdaq Capital Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 2.93 | -8.15 % | $ 4.82 M | NYSE American | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
- | -9.21 % | $ 2.55 M | Nasdaq Global Market | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
- | -5.68 % | $ 8.28 M | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Evogene Ltd.
EVGN
|
$ 0.81 | 3.33 % | $ 27.9 M | Nasdaq Global Market | Israel |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.